செல்லுலார் சிகிச்சை துறை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from செல்லுலார் சிகிச்சை துறை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In செல்லுலார் சிகிச்சை துறை Today - Breaking & Trending Today

MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications


MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications
MaaT011 was safe after induction chemotherapy in acute myeloid leukemia patients
MaaT011 formed the basis of the company s full ecosystem therapeutic approach that was continued with product candidatesMaaT013 (in acute graft-vs-host disease) and MaaT033 (in acute myeloid leukemia)
MaaT Pharma announced today that final results from its Phase 1/2 ODYSSEE clinical trial have been published in the journal,
Nature Communications. The data
demonstrated that the company s initial product candidate, MaaT011, an autologous fecal microbiota transfer treatment, was safe and effective in fully restoring the gut microbiota in the 20 per-protocol analyses set of acute myeloid leukemia (AML) patients. In addition, the MaaT011 treatment showed short- and long-term signs of positive clinical outcomes including the reduction of both intestinal inflammatio ....

Saint Antoine , United States , France General , City Of , United Kingdom , Kostenloser Wertpapierhandel , John Weinberg , Mohamad Mohty , American Society Of Hematology , Nature Communications , Cellular Therapy Department , Trophic Communications , Professor Of Hematology At Sorbonne University , American Society , Annual Meeting , Maat Pharma , Chief Medical Officer , Sorbonne University , Saint Antoine Hospital , Acute Myeloid Leukemia , Microbiome Ecosystem Therapies , Stephanie May , துறவி அன்டோயின் , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , நகரம் ஆஃப் ,

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease


(0)
Study meets primary and key secondary objectives with positive impact and favorable overall safety profile in 21 heavily pre-treated and immunocompromised patients with steroid-resistant, gastrointestinal-predominant aGvHD following stem cell transplantation
Results in line with previously observed data from a larger patient population treated with MaaT013 as part of an early access program
MaaT013 expected to advance into pivotal Phase 3 program
MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease (SR-GI-aGvHD). The study met its primary endpoint of clinical efficacy, demonstrating a combined 33.3% complete response rate (CR) or very good partial response rate (VGPR) at day 28. In addition, the overall response rate (ORR) was 38.1% at da ....

Saint Antoine , France General , Kostenloser Wertpapierhandel , John Weinberg , Mohamad Mohty , Cellular Therapy Department , European Medicines Agency , Professor Of Haematology At Sorbonne University , Drug Administration , Trophic Communications , Maat Pharma , Chief Medical Officer , Sorbonne University , Saint Antoine Hospital , Orphan Drug Designation , Microbiome Ecosystem Therapies , Stephanie May , Top Line , துறவி அன்டோயின் , பிரான்ஸ் ஜநரல் , ஜான் வெயின்பெர்க் , செல்லுலார் சிகிச்சை துறை , ப்ரொஃபெஸர் ஆஃப் ஹீமாட்டாலஜி இல் சோர்போன் பல்கலைக்கழகம் , ம்யாயாட் பார்மா , தலைமை மருத்துவ அதிகாரி , சோர்போன் பல்கலைக்கழகம் ,